Arrhythmias & electrophysiologyCohort study
Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation
- Population-based cohort study
- prevalent new-user design
- 1:1 time-conditional propensity-score matched
Authors' conclusion
Among patients with DM and pre-existing AF, SGLT2is are associated with decreased AF-related health resource utilization and improved arrhythmic outcomes compared with DPP4is.
Study context
- Population
- Adults with diabetes mellitus (DM) and pre-existing atrial fibrillation (AF), 2014–2019
- Participants
- 2,242 adults
- Exposure
- SGLT2i vs DPP4i
- Outcome
- Composite of AF-related healthcare utilization (hospitalization, ED visits, electrical cardioversion or catheter ablation)
- Follow-up
- Average 3.0 years
Main finding
As reported in the abstract
Adjusted hazard ratio
0.73
95% CI 0.55–0.96
P = 0.03
Events by group
SGLT2i vs DPP4i
adjusted HR 0.73 (95% CI 0.55–0.96); P = 0.03
Observational data: associations, not effects.
Secondary outcomes
All-cause mortality and heart failure (HF) hospitalization
- Significant reductions with SGLT2i
Ischaemic stroke/transient ischaemic attack (TIA)
- No difference in risk
Original publication
Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation. Europace. Published 14 March 2024. doi:10.1093/europace/euae054
Summarised from the published abstract; every number is checked against it